CClinicalTrials.gg
CompletedNCT06736821melatoninUpdated Aug 12, 2025

Maxillary Sinus Augmentation by Xenograft Mixed With Melatonin

An interventional study of Open sinus augmentation with melatonin gel mixed with xenograft and Open sinus augmentation with xenograft in Bone Healing, sponsored by rehab soliman. Completed at 1 site in Egypt. Open to participants aged 25 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-08-12.

Sponsored by rehab soliman · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 10 months after the study started (first participant enrolled Jan 2024, registered Dec 2024).
Phase
Not applicable
Study type
Interventional
Enrollment
16
Allocation
Randomized
Ages
25 Years and older
Sex
All
01

Study summary

The possibility of enhancing the bone substitute in the maxillary sinus by mixing it with the melatonin to allow proper implant placement in early stage .

The aim of the study was to evaluate clinically, radiographically and histologically the effect of melatonin in enhancement of bone healing after augmentation of the maxillary sinus.

Read the detailed description

This study was include 16 severely atrophied maxillary sinus, with alveolar bone height less than 4mm, that need sinus augmentation and delayed implant placement, they were be equally and randomly distributed into 2 groups (via : http://www.randomizer.org) :

Group A: sinuses was received sinus membrane elevation using lateral window technique and filling the sinus with the mixture of melatonin and xenograft.

Group B: sinuses was received sinus membrane elevation using lateral window technique and filling the sinus with xenograft.

After 6 months, bone biopsies was collected from the augmented sinuses immediately before implant instalment in the same visit.

Initial cone beam computerized tomography was taken preoperatively and immediate postoperatively.

Final cone beam computerized tomography was taken 6 months before implant placement to measure Bone density and bone height and width.

After 3 months of implant placement, the installed implants was assessed clinically to exclude any infection or dehiscence and radio graphically to assess the bone loss or any radiolucent lesion around the implants and then prepared for loading.

02

Conditions studied

  • Bone Healing

Keywords

  • sinus lifting
  • maxillary sinus augmentation
  • melatonin gel
03

In context

Lead sponsor

rehab soliman is the lead sponsor of 2 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
25 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  1. Adult male/female patients above the age of 25.
  2. Patients with one or more teeth requiring implant supported dental restoration in atrophic maxilla (unilateral or bilateral).
  3. Alveolar bone height less than 4 mm at the defective site.
  4. Good oral hygiene.

Exclusion criteria

Exclusion Criteria:

  1. Medically compromised patients with conditions contraindicating surgery (eg. uncontrolled diabetics, bisphosphonate intake, radio or chemotherapy).
  2. Patients with active infection at or related to the site of surgery (eg. acute sinusitis).
  3. Heavy smokers.
  4. Patients not indicated for an implant supported restoration at the time of enrollment (eg. active/untreated periodontal disease).
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
16 participants (actual)

Study arms

  • Experimental
    group a: xenograft mixed with melatonin

    in this group, the patients underwent open sinus lifting surgery and augmentation of the sinuses by xenograft mixed with melatonin gel to enhance the bone healing

    Dietary Supplement: Open sinus augmentation with melatonin gel mixed with xenograft

  • Active comparator
    group b: xenograft

    in this group, the patients underwent open sinus lifting surgery and augmentation of the sinuses by xenograft without any additives

    Procedure: Open sinus augmentation with xenograft

Interventions

  • Dietary supplementOpen sinus augmentation with melatonin gel mixed with xenograft

    All Patients in this group underwent open sinus procedures to lift the sinus membrane followed by application of the melatonin gel which was mixed with xenograft as an augmentation material. Preclinical studies proved the direct action of melatonin in enhancing the differentiation and proliferation of bone-forming osteoblasts. In addition to increasing bone mass, melatonin also facilitates new bone growth and osteointegration, making melatonin a particularly attractive molecule for use in bone implants when used alone or in combination with other growth factors

    Also known as: Primary intervention

  • ProcedureOpen sinus augmentation with xenograft

    All Patients in this group underwent open sinus procedures to lift the sinus membrane followed by application of the xenograft as an augmentation material xenograft is used instead of autogenous bone graft to avoid the morbidity of the donor side

    Also known as: Secondary Intervention

06

What researchers measure

Primary outcomes

  1. Alveolar Bone Height

    Alveolar Bone height was measured using cone beam computed tomography (CBCT).

    Time frame: 8 months

Secondary outcomes

  1. Histological Analysis of Newly Formed Bone

    The quality of the newly formed bone was evaluated using two histological stains: Hematoxylin and Eosin, and Masson's Trichrome.

    Time frame: 8 months

07

Study locations

1 site
  • Suez Canal University
    Ismailia, 41522, Egypt
08

References and documents

Publications

  • ElSholkamy M, Makawi DM, ElKhateeb SM, Soliman T, Soliman RA. Clinical, radiographic and histomorphometric assessment of the effects of melatonin gel mixed with a xenograft in augmentation of the maxillary sinus: a randomized controlled clinical trial. BMC Oral Health. 2026 Apr 16;26(1):732. doi: 10.1186/s12903-026-08201-0. PubMed 41987188 ↗

Individual participant data

Plan to share: No

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 12, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06736821
Lead sponsor
rehab soliman
Responsible party
rehab soliman (lecturer of oral and maxillofacial department, Ain Shams University) — Sponsor-investigator
First posted
Dec 17, 2024
Start date
Jan 9, 2024
Primary completion
Jul 23, 2024
Completion
Aug 27, 2024
Last update
Aug 12, 2025

Study contacts

rehab soliman
principal investigator · Misr International University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion